

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.3. Antiretrovirals > Protease inhibitors

EMLc

Codes ATC: J05AE01

| | |
|-------------------------------------|---|
| Indication | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Code ICD11: 1C62.Z |
| INN | Saquinavir |
| Type de médicament | Chemical agent |
| Type de liste | Liste de base (EML) (EMLc) |
| Formulations | Oral > Solid: 200 mg ; 500 mg |
| Historique des statuts LME | Ajouté pour la première fois en 2002 (TRS 914) Modifié en 2007 (TRS 950) Modifié en 2009 (TRS 958) Retiré en 2017 (TRS 1006) |
| Sexe | Tous |
| Âge | Aussi recommandé pour les enfants |
| Restriction de poids | > 25 kg |
| Équivalence thérapeutique | La recommandation concerne ce médicament spécifique |
| Renseignements sur le brevet | Patents have expired in most jurisdictions Lire la suite sur les brevets .  |
| Wikipédia | Saquinavir  |
| DrugBank | Saquinavir  |

Résumé des preuves et recommandation du comité d'experts

The Expert Committee recommended the deletion of saquinavir from the Model Lists, noting that the clinical use of the protease inhibitor saquinavir has declined over time with the introduction of newer antiretroviral agents with lower pill burden, similar or greater effectiveness and lower risk of toxicity. Unlike other protease inhibitors, saquinavir is associated with QT prolongation and a requirement for ECG monitoring. Numerous alternative protease inhibitors (with and without ritonavir) remain listed on the EML.

